IN8bio, Inc.
INAB
$1.10
-$0.08-6.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.20% | -16.99% | -23.64% | -24.37% | -21.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.97% | -26.85% | -32.90% | -32.75% | -28.69% |
| Operating Income | 16.97% | 26.85% | 32.90% | 32.75% | 28.69% |
| Income Before Tax | 21.86% | 30.79% | 36.13% | 35.19% | 25.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.86% | 30.79% | 36.13% | 35.19% | 25.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.86% | 30.79% | 36.13% | 35.19% | 25.25% |
| EBIT | 16.97% | 26.85% | 32.90% | 32.75% | 28.69% |
| EBITDA | 15.75% | 27.85% | 34.84% | 35.05% | 31.04% |
| EPS Basic | 79.99% | 79.05% | 73.03% | 70.62% | 58.70% |
| Normalized Basic EPS | 78.58% | 78.03% | 72.00% | 69.71% | 61.43% |
| EPS Diluted | 79.99% | 79.05% | 73.03% | 70.62% | 58.70% |
| Normalized Diluted EPS | 78.58% | 78.03% | 72.00% | 69.71% | 61.43% |
| Average Basic Shares Outstanding | 365.40% | 323.67% | 155.27% | 140.81% | 108.34% |
| Average Diluted Shares Outstanding | 365.40% | 323.67% | 155.27% | 140.81% | 108.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |